{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:08:39Z","timestamp":1791216519666,"version":"4.1.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1097\/md.0000000000005229","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T06:44:44Z","timestamp":1477464284000},"page":"e5229","source":"Crossref","is-referenced-by-count":13,"title":["Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes"],"prefix":"10.1097","volume":"95","author":[{"given":"Feng-fei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-lan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reng-na","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-fei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-dan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-hua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-35-20210309","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(08)60736-9","article-title":"Intensive insulin therapy in newly diagnosed type 2 diabetes","volume":"371","author":"Retnakaran","year":"2008","journal-title":"Lancet"},{"key":"R2-35-20210309","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2337\/diacare.20.9.1353","article-title":"Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment","volume":"20","author":"Ilkova","year":"1997","journal-title":"Diabetes Care"},{"key":"R3-35-20210309","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.2337\/diacare.27.11.2597","article-title":"Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function","volume":"27","author":"Li","year":"2004","journal-title":"Diabetes Care"},{"key":"R4-35-20210309","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.2337\/diacare.27.5.1028","article-title":"Short-term intensive insulin therapy in newly diagnosed type 2 diabetes","volume":"27","author":"Ryan","year":"2004","journal-title":"Diabetes Care"},{"key":"R5-35-20210309","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(08)60762-X","article-title":"Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial","volume":"371","author":"Weng","year":"2008","journal-title":"Lancet"},{"key":"R6-35-20210309","doi-asserted-by":"crossref","first-page":"1028945","DOI":"10.1155\/2016\/1028945","article-title":"Blood glucose fluctuations in type 2 diabetes patients treated with multiple daily injections","volume":"2016","author":"Li","year":"2016","journal-title":"J Diabetes Res"},{"key":"R7-35-20210309","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2337\/diacare.22.2.233","article-title":"The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years","volume":"22","author":"Coutinho","year":"1999","journal-title":"Diabetes Care"},{"key":"R8-35-20210309","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinte.161.3.397","article-title":"European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria.","volume":"161","year":"2001","journal-title":"Arch Intern Med"},{"key":"R9-35-20210309","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"R10-35-20210309","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00125-004-1334-6","article-title":"Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin","volume":"47","author":"Nakagami","year":"2004","journal-title":"Diabetologia"},{"key":"R11-35-20210309","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1021\/jm050261p","article-title":"Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes","volume":"48","author":"Augeri","year":"2005","journal-title":"J Med Chem"},{"key":"R12-35-20210309","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2165\/11201170-000000000-00000","article-title":"Saxagliptin","volume":"69","author":"Dhillon","year":"2009","journal-title":"Drugs"},{"key":"R13-35-20210309","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1758-5996-4-36","article-title":"The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"4","author":"Frederich","year":"2012","journal-title":"Diabetol Metab Syndr"},{"key":"R14-35-20210309","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/dmrr.1306","article-title":"Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"28","author":"Pan","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"key":"R15-35-20210309","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1185\/03007990903178735","article-title":"Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes","volume":"25","author":"Rosenstock","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"R16-35-20210309","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s12325-015-0262-9","article-title":"Utility of saxagliptin in the treatment of type 2 diabetes: review of efficacy and safety","volume":"32","author":"Jain","year":"2015","journal-title":"Adv Ther"},{"key":"R17-35-20210309","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2337\/dc08-1984","article-title":"The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone","volume":"32","author":"DeFronzo","year":"2009","journal-title":"Diabetes Care"},{"key":"R18-35-20210309","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1185\/03007995.2012.735646","article-title":"Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study","volume":"28","author":"Hermans","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"R19-35-20210309","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.diabres.2011.07.035","article-title":"Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial","volume":"94","author":"Yang","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"R20-35-20210309","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1185\/03007995.2012.665046","article-title":"Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin","volume":"28","author":"Barnett","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"R21-35-20210309","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1185\/03007995.2016.1162773","article-title":"Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea","volume":"32","author":"Xiaoyan","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"R22-35-20210309","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1463-1326.2011.01417.x","article-title":"Effects of saxagliptin on beta-cell stimulation and insulin secretion in patients with type 2 diabetes","volume":"13","author":"Henry","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"R23-35-20210309","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bbrc.2016.02.019","article-title":"Reduced DPP4 activity improves insulin signaling in primary human adipocytes","volume":"471","author":"Rohrborn","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"R24-35-20210309","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1089\/dia.2013.0090","article-title":"ProAct study: new features of insulin pumps improve diabetes management and glycemic control in patients after transition of continuous subcutaneous insulin infusion systems","volume":"15","author":"Ziegler","year":"2013","journal-title":"Diabetes Technol Ther"},{"key":"R25-35-20210309","doi-asserted-by":"crossref","first-page":"903524","DOI":"10.1155\/2015\/903524","article-title":"Influence of acarbose on plasma glucose fluctuations in insulin-treated patients with type 2 diabetes: a pilot study","volume":"2015","author":"Li","year":"2015","journal-title":"Int J Endocrinol"},{"key":"R26-35-20210309","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1463-1326.2006.00666.x","article-title":"Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy","volume":"9","author":"Schnell","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"R27-35-20210309","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1742-1241.2006.01178.x","article-title":"DPP-4 inhibitors and their potential role in the management of type 2 diabetes","volume":"60","author":"Barnett","year":"2006","journal-title":"Int J Clin Pract"},{"key":"R28-35-20210309","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1172\/JCI30076","article-title":"The role of gut hormones in glucose homeostasis","volume":"117","author":"Drucker","year":"2007","journal-title":"J Clin Invest"},{"key":"R29-35-20210309","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2337\/dc15-2763","article-title":"Predisposing factors for any and major hypoglycemia with saxagliptin versus placebo and overall: analysis from the SAVOR-TIMI 53 trial","volume":"39","author":"Cahn","year":"2016","journal-title":"Diabetes Care"},{"key":"R30-35-20210309","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/M15-2568","article-title":"Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study","volume":"164","author":"Toh","year":"2016","journal-title":"Ann Intern Med"},{"key":"R31-35-20210309","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.295.14.1681","article-title":"Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes","volume":"295","author":"Monnier","year":"2006","journal-title":"JAMA"},{"key":"R32-35-20210309","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2337\/diacare.25.8.1439","article-title":"Role of hyperglycemia in nitrotyrosine postprandial generation","volume":"25","author":"Ceriello","year":"2002","journal-title":"Diabetes Care"},{"key":"R33-35-20210309","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"R34-35-20210309","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1463-1326.2010.01317.x","article-title":"Pharmacological management of type 2 diabetes: the potential of incretin-based therapies","volume":"13","author":"Charbonnel","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"R35-35-20210309","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/j.1742-1241.2009.02332.x","article-title":"Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes","volume":"64","author":"Barnett","year":"2010","journal-title":"Int J Clin Pract"},{"key":"R36-35-20210309","first-page":"253","article-title":"[Development and interpretation of China medical nutrition therapy guideline for diabetes (2010)]","volume":"33","author":"Chen","year":"2011","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"R37-35-20210309","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/1753-0407.12058","article-title":"Interpretation of Chinese Society of Endocrinology consensus statement on hyperglycemia management target in adult inpatients in China","volume":"5","author":"Lu","year":"2013","journal-title":"J Diabetes"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000005229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:36:20Z","timestamp":1620959780000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201610250-00035"}},"subtitle":["A randomized, control, open-labeled trial"],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":37,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000005229","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}